207 related articles for article (PubMed ID: 6499356)
21. S-mephenytoin hydroxylation phenotypes in a Jordanian population.
Hadidi HF; Irshaid YM; Woosley RL; Idle JR; Flockhart DA
Clin Pharmacol Ther; 1995 Nov; 58(5):542-7. PubMed ID: 7586948
[TBL] [Abstract][Full Text] [Related]
22. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
24. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
Schellens JH; van der Wart JH; Breimer DD
Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
[TBL] [Abstract][Full Text] [Related]
25. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
Küpfer A; Brilis GM; Watson JT; Harris TM
Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
[TBL] [Abstract][Full Text] [Related]
26. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
[TBL] [Abstract][Full Text] [Related]
27. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
[TBL] [Abstract][Full Text] [Related]
28. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
29. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
30. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
[TBL] [Abstract][Full Text] [Related]
32. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
33. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
[TBL] [Abstract][Full Text] [Related]
34. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
35. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].
Kuang TY; Liao XM; Wang KY; Zhang Y; Lou YQ
Yao Xue Xue Bao; 1991; 26(4):250-4. PubMed ID: 1957669
[TBL] [Abstract][Full Text] [Related]
36. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Alván G; Bechtel P; Iselius L; Gundert-Remy U
Eur J Clin Pharmacol; 1990; 39(6):533-7. PubMed ID: 2151318
[TBL] [Abstract][Full Text] [Related]
37. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
[TBL] [Abstract][Full Text] [Related]
38. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
39. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
Tybring G; Bertilsson L
Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124
[TBL] [Abstract][Full Text] [Related]
40. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
